McKesson Lifts Fiscal Outlook as Oncology Strategy Expands

McKesson raised its fiscal 2027 adjusted earnings outlook by 40 cents after a first quarter in which oncology and technology businesses outpaced the company’s core distribution operation.

The healthcare services company now expects adjusted earnings per share of $44.20 to $45.00, up from its previous range of $43.80 to $44.60. The new forecast implies reported growth of roughly 13% to 15%, or 15% to 17% after excluding the effects of McKesson’s exit from Norway and a prior-year gain tied to the sale of part of its U.S. Oncology business.

The upgrade gives investors a cleaner view of where McKesson is putting its growth capital. Oncology and Multispecialty revenue rose 33% in the quarter, while adjusted operating profit climbed about 41%. Even excluding the contribution from the Core Ventures acquisition, operating profit growth was roughly 15%, near the middle of McKesson’s full-year target.

That momentum is central to the company’s planned $2.25 billion acquisition of Precision Medicine Group, announced August 25 and still awaiting regulatory clearance. Precision Medicine provides clinical research and biopharma commercialization services, including contract research, payer strategy and market-access support. McKesson intends to place the business inside its Oncology & Multispecialty segment.

The strategic logic is less about adding another distributor and more about connecting pieces of an oncology ecosystem. Precision Medicine’s trial operations would sit alongside Sarah Cannon Research Institute, Ontada’s real-world oncology data and analytics platform, and The US Oncology Network, which McKesson said has about 3,400 providers.

Chief Executive Brian Tyler said the combination could help drugmakers enroll community-based patients in trials faster, while giving patients access to research outside major academic medical centers. McKesson says Sarah Cannon helped manage trials for 43 of the 52 adult oncology drugs that reached the market in 2025.

The quarter was not uniformly strong. Prescription Technology Solutions posted 9% revenue growth and 13% adjusted operating profit growth, while North American Pharmaceutical revenue increased 5% and profit rose 19%. Medical-Surgical revenue grew 4%, but adjusted operating profit fell about 20% because of product mix and one-time administrative costs.

That business, now called Wellverse, remains targeted for a potential second-half 2027 IPO. For now, McKesson is signaling that oncology and biopharma services, not medical supplies, will carry the company’s longer-term growth narrative.